USD 10.04
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| BVS | -0.7 | 14.5 | -5.9 | -22.5 | 40.0 | 108.7 | -29.4 | -47.7 | -47.7 | -47.7 |
| S&P 500 | 1.0 | 1.5 | 1.1 | 2.3 | 8.9 | 23.6 | 33.8 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | BVS |
| name | Bioventus Inc. |
| price | 10.04 |
| changes percentage | -0.6924 |
| change | -0.07 |
| day low | 9.865 |
| day high | 10.25 |
| year high | 14.38 |
| year low | 3.9 |
| market cap | 656292712 |
| price avg 50 | 11.0628 |
| price avg 200 | 8.7393 |
| exchange | NASDAQ |
| volume | 362891 |
| avg volume | 378929 |
| open | 10.15 |
| previous close | 10.11 |
| eps | -0.61 |
| pe | -16.46 |
| earnings announcement | 2025-03-10T12:30:00.000+0000 |
| shares outstanding | 65367800 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001665988 | |||
| revenue | 512345000 | 512117000 | 0.04 |
| gross profit | 328193000 | 331080000 | -0.87 |
| gross profit ratio | 0.64 | 0.65 | -0.92 |
| research and development expenses | 13446000 | 25941000 | -48.17 |
| operating expenses | 409918000 | 379700000 | 7.96 |
| interest income | 0 | 25795000 | -100.00 |
| interest expense | 40676000 | 25795000 | 57.69 |
| ebitda | -23070000 | -109205000 | 78.87 |
| ebitdaratio | -0.05 | 0.06 | -174.08 |
| operating income | -81725000 | -35676000 | -129.08 |
| operating income ratio | -0.16 | -0.07 | -128.97 |
| net income | -156230000 | -213391000 | 26.79 |
| net income ratio | -0.3 | -0.42 | 26.82 |
| eps | -2.49 | -3.48 | 28.45 |
Revenue Growth: revenue increased to 512 million in 2023 from 512 million in 2022 representing a change of 0.04%. This indicates a sales growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -23 million in 2023 from -109 million in 2022 representing a change of 78.87%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -82 million in 2023 from -36 million in 2022 representing a change of -129.08%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -2.49 in 2023 from -2.49 in 2022 representing a change of 28.45%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to 328 million in 2023 from 331 million in 2022 representing a change of -0.87%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 13 million in 2023 from 26 million in 2022 representing a change of -48.17%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 410 million in 2023 from 380 million in 2022 representing a change of 7.96%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -156 million in 2023 from -213 million in 2022 representing a change of 26.79%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001665988 | |||
| revenue | 138964000 | 151217000 | -8.10 |
| gross profit | 93551000 | 101575000 | -7.90 |
| gross profit ratio | 0.67 | 0.67 | 0.22 |
| research and development expenses | 3808000 | 3988000 | -4.51 |
| operating expenses | 84898000 | 95928000 | -11.50 |
| interest income | 0 | 0 | NaN |
| interest expense | 9532000 | 9924000 | -3.95 |
| ebitda | 16975000 | -16437000 | 203.27 |
| ebitdaratio | 0.12 | 0.12 | -1.42 |
| operating income | 4074000 | 5647000 | -27.86 |
| operating income ratio | 0.03 | 0.04 | -21.49 |
| net income | -4824000 | -23992000 | 79.89 |
| net income ratio | -0.03 | -0.16 | 78.12 |
| eps | -0.07 | -0.37 | 80.03 |
Revenue Growth: revenue decreased to 139 million in 2024Q3 from 151 million in 2024Q2 representing a change of -8.1%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 94 million in 2024Q3 from 102 million in 2024Q2 representing a change of -7.9%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 4 million in 2024Q3 from 4 million in 2024Q2 representing a change of -4.51%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Income: Operating income decreased to 4 million in 2024Q3 from 6 million in 2024Q2 representing a change of -27.86%. The decrease in operating income indicates worse operational performance and decreased profitability.
Operating Expenses: Operating Expenses decreased to 85 million in 2024Q3 from 96 million in 2024Q2 representing a change of -11.5%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 17 million in 2024Q3 from -16 million in 2024Q2 representing a change of 203.27%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to -5 million in 2024Q3 from -24 million in 2024Q2 representing a change of 79.89%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.07 in 2024Q3 from -0.07 in 2024Q2 representing a change of 80.03%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001665988 | |||
| total assets | 810910000 | 1372649000 | -40.92 |
| total liabilities | 589792000 | 1032317000 | -42.87 |
| total equity | 221118000 | 340332000 | -35.03 |
| cash and cash equivalents | 36964000 | 31814000 | 16.19 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 2636000 | -100.00 |
| total current assets | 267999000 | 272575000 | -1.68 |
| total non current assets | 542911000 | 1100074000 | -50.65 |
| total current liabilities | 175497000 | 304017000 | -42.27 |
| total non current liabilities | 414295000 | 728300000 | -43.11 |
| common stock | 79000 | 78000 | 1.28 |
| retained earnings | -321536000 | -165306000 | -94.51 |
| total debt | 394846000 | 418066000 | -5.55 |
Total Assets: Total Assets decreased to 811 million in 2023 from 1,373 million in 2022 representing a change of -40.92%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 221 million in 2023 from 340 million in 2022 representing a change of -35.03%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 268 million in 2023 from 273 million in 2022 representing a change of -1.68%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -322 million in 2023 from -165 million in 2022 representing a change of -94.51%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 590 million in 2023 from 1,032 million in 2022 representing a change of -42.87%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 37 million in 2023 from 32 million in 2022 representing a change of 16.19%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 175 million in 2023 from 304 million in 2022 representing a change of -42.27%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 1.28%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 395 million in 2023 from 418 million in 2022 representing a change of -5.55%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001665988 | |||
| total assets | 769492000 | 792173000 | -2.86 |
| total liabilities | 582659000 | 603111000 | -3.39 |
| total equity | 186833000 | 189062000 | -1.18 |
| cash and cash equivalents | 43074000 | 31994000 | 34.63 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 2088000 | -100.00 |
| total current assets | 298688000 | 308883000 | -3.30 |
| total non current assets | 470804000 | 483290000 | -2.58 |
| total current liabilities | 211492000 | 231463000 | -8.63 |
| total non current liabilities | 371167000 | 371648000 | -0.13 |
| common stock | 81000 | 81000 | 0.00 |
| retained earnings | -354922000 | -350098000 | -1.38 |
| total debt | 383587000 | 394789000 | -2.84 |
Total Assets: Total Assets decreased to 769 million in 2024Q3 from 792 million in 2024Q2 representing a change of -2.86%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 187 million in 2024Q3 from 189 million in 2024Q2 representing a change of -1.18%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 299 million in 2024Q3 from 309 million in 2024Q2 representing a change of -3.3%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -355 million in 2024Q3 from -350 million in 2024Q2 representing a change of -1.38%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 583 million in 2024Q3 from 603 million in 2024Q2 representing a change of -3.39%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 43 million in 2024Q3 from 32 million in 2024Q2 representing a change of 34.63%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 211 million in 2024Q3 from 231 million in 2024Q2 representing a change of -8.63%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 384 million in 2024Q3 from 395 million in 2024Q2 representing a change of -2.84%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001665988 | |||
| net change in cash | 5127000 | -67376000 | 107.61 |
| operating cash flow | 15344000 | -13537000 | 213.35 |
| free cash flow | 7982000 | -25057000 | 131.86 |
| capital expenditure | -7362000 | -11520000 | 36.09 |
| depreciation and amortization | 57365000 | 66803000 | -14.13 |
| deferred income tax | -2377000 | -52792000 | 95.50 |
| stock based compensation | 2722000 | 17585000 | -84.52 |
| accounts payables | 0 | 10913 | -100.00 |
| inventory | 0 | -18618000 | 100.00 |
| acquisitions net | 34675000 | -104841000 | 133.07 |
| investments in property plant and equipment | -7362000 | -11520000 | 36.09 |
| net cash used for investing activites | 15807000 | -116436000 | 113.58 |
| debt repayment | -23264000 | 59621000 | -139.02 |
| common stock issued | 778000 | 5822000 | -86.64 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -26653000 | 62076000 | -142.94 |
| cash at end of period | 36964000 | 31837000 | 16.10 |
| accounts receivables | 10055000 | -18022000 | 155.79 |
| cash at beginning of period | 31837000 | 99213000 | -67.91 |
Net Change in Cash: Net Change in Cash increased to 5 million in 2023 from -67 million in 2022 representing a change of 107.61%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 15 million in 2023 from -14 million in 2022 representing a change of 213.35%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 8 million in 2023 from -25 million in 2022 representing a change of 131.86%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 3 million in 2023 from 18 million in 2022 representing a change of -84.52%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2023 from 0 million in 2022 representing a change of -100.0%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -7 million in 2023 from -12 million in 2022 representing a change of 36.09%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -2 million in 2023 from -53 million in 2022 representing a change of 95.5%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 10 in 2023 from -18 million in 2022 representing a change of 155.79%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001665988 | |||
| operating cash flow | 10316000 | 15162000 | -31.96 |
| free cash flow | 10252000 | 15085000 | -32.04 |
| capital expenditure | -64000 | -77000 | 16.88 |
| depreciation and amortization | 12275000 | 13090000 | -6.23 |
| deferred income tax | -511000 | -8179000 | 93.75 |
| stock based compensation | 2064000 | 3672000 | -43.79 |
| accounts receivables | 17059000 | -19975000 | 185.40 |
| accounts payables | -21328000 | 29884000 | -171.37 |
| inventory | -2515000 | -4289000 | 41.36 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 645000 | -77000 | 937.66 |
| net cash used for investing activites | -64000 | -77000 | 16.88 |
| debt repayment | 0 | -8263999 | 100.00 |
| common stock issued | 553000 | 609000 | -9.20 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 362000 | -7845000 | 104.61 |
| net change in cash | 11080000 | 6821000 | 62.44 |
| cash at end of period | 43074000 | 31994000 | 34.63 |
| cash at beginning of period | 31994000 | 25173000 | 27.10 |
Net Change in Cash: Net Change in Cash increased to 11 million in 2024Q3 from 7 million in 2024Q2 representing a change of 62.44%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation decreased to 2 million in 2024Q3 from 4 million in 2024Q2 representing a change of -43.79%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 21 million in 2024Q3 from 30 million in 2024Q2 representing a change of -171.37%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow decreased to 10 million in 2024Q3 from 15 million in 2024Q2 representing a change of -31.96%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 10 million in 2024Q3 from 15 million in 2024Q2 representing a change of -32.04%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 16.88%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -1 million in 2024Q3 from -8 million in 2024Q2 representing a change of 93.75%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 17 in 2024Q3 from -20 million in 2024Q2 representing a change of 185.4%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 8.18 | 8.34 | -1.97 |
| net income per share | -2.49 | -3.48 | 28.26 |
| operating cash flow per share | 0.24 | -0.22 | 211.07 |
| free cash flow per share | 0.13 | -0.41 | 131.22 |
| cash per share | 0.59 | 0.52 | 13.85 |
| book value per share | 3.53 | 5.54 | -36.33 |
| tangible book value per share | -4.29 | -11.6 | 63.03 |
| shareholders equity per share | 2.77 | 5.16 | -46.27 |
| interest debt per share | 6.95 | 7.23 | -3.85 |
| market cap | 330152609.58 | 160225569.27 | 106.05 |
| enterprise value | 688034609.58 | 546477569.27 | 25.90 |
| pe ratio | -2.11 | -0.75 | -181.45 |
| price to sales ratio | 0.64 | 0.31 | 105.96 |
| pocfratio | 21.52 | -11.84 | 281.79 |
| pfcf ratio | 41.36 | -6.39 | 746.85 |
| pb ratio | 1.9 | 0.51 | 275.79 |
| ptb ratio | 1.9 | 0.51 | 275.79 |
| ev to sales | 1.34 | 1.07 | 25.85 |
| enterprise value over ebitda | -29.82 | -5.0 | -495.98 |
| ev to operating cash flow | 44.84 | -40.37 | 211.08 |
| ev to free cash flow | 86.2 | -21.81 | 495.23 |
| earnings yield | -0.47 | -1.33 | 64.47 |
| free cash flow yield | 0.02 | -0.16 | 115.46 |
| debt to equity | 2.27 | 1.32 | 72.24 |
| debt to assets | 0.49 | 0.3 | 59.87 |
| net debt to ebitda | -15.51 | -3.54 | -338.60 |
| current ratio | 1.53 | 0.9 | 70.32 |
| interest coverage | -2.01 | -1.38 | -45.27 |
| income quality | -0.13 | 0.06 | -299.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.59 | 0.64 | -8.40 |
| research and ddevelopement to revenue | 0.03 | 0.05 | -48.19 |
| intangibles to total assets | 0.6 | 0.77 | -21.22 |
| capex to operating cash flow | 0.48 | -0.85 | 156.38 |
| capex to revenue | 0.01 | 0.02 | -36.12 |
| capex to depreciation | 0.13 | 0.17 | -25.58 |
| stock based compensation to revenue | 0.01 | 0.03 | -84.53 |
| graham number | 12.47 | 20.08 | -37.91 |
| roic | -0.12 | -0.03 | -370.89 |
| return on tangible assets | -0.49 | -0.67 | 27.00 |
| graham net net | -6.62 | -13.93 | 52.47 |
| working capital | 92502000 | -31442000 | 394.20 |
| tangible asset value | -268694000 | -712151000 | 62.27 |
| net current asset value | -321793000 | -759742000 | 57.64 |
| invested capital | 632272000 | 1065996000 | -40.69 |
| average receivables | 129804000 | 130803500 | -0.76 |
| average payables | 29867500 | 26806000 | 11.42 |
| average inventory | 88370500 | 73548000 | 20.15 |
| days sales outstanding | 87.66 | 97.33 | -9.94 |
| days payables outstanding | 45.66 | 73.99 | -38.28 |
| days of inventory on hand | 181.03 | 172.2 | 5.13 |
| receivables turnover | 4.16 | 3.75 | 11.03 |
| payables turnover | 7.99 | 4.93 | 62.03 |
| inventory turnover | 2.02 | 2.12 | -4.88 |
| roe | -0.9 | -0.67 | -33.52 |
| capex per share | 0.12 | 0.19 | -37.38 |
ROE: Return on Equity (ROE) decreased to -0.90 on 2023-12-31 from -0.67 on 2022-12-31, representing a change of -33.52%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.11 on 2023-12-31 from -0.75 on 2022-12-31, representing a change of -181.45%. Indicating a decrease in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 2.27 on 2023-12-31 from 1.32 on 2022-12-31, representing a change of 72.24%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
Current Ratio: Current Ratio increased to 1.53 on 2023-12-31 from 0.90 on 2022-12-31, representing a change of 70.32%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
| 2024-09-28 Q3 | 2024-06-29 Q2 | Q/Q change % | |
|---|---|---|---|
| BVS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 2.13 | 2.36 | -9.80 |
| net income per share | -0.07 | -0.37 | 80.26 |
| operating cash flow per share | 0.16 | 0.24 | -33.21 |
| free cash flow per share | 0.16 | 0.24 | -33.29 |
| cash per share | 0.66 | 0.5 | 32.15 |
| book value per share | 2.86 | 2.95 | -3.00 |
| tangible book value per share | -3.61 | -3.79 | 4.88 |
| shareholders equity per share | 2.28 | 2.36 | -3.27 |
| interest debt per share | 6.02 | 6.32 | -4.65 |
| market cap | 759608090.28 | 368326364.25 | 106.23 |
| enterprise value | 1100121090.28 | 731121364.25 | 50.47 |
| pe ratio | -39.37 | -3.84 | -925.69 |
| price to sales ratio | 5.47 | 2.44 | 124.42 |
| pocfratio | 73.63 | 24.29 | 203.11 |
| pfcf ratio | 74.09 | 24.42 | 203.45 |
| pb ratio | 5.11 | 2.44 | 109.28 |
| ptb ratio | 5.11 | 2.44 | 109.28 |
| ev to sales | 7.92 | 4.83 | 63.74 |
| enterprise value over ebitda | 64.81 | -44.48 | 245.70 |
| ev to operating cash flow | 106.64 | 48.22 | 121.15 |
| ev to free cash flow | 107.31 | 48.47 | 121.41 |
| earnings yield | -0.01 | -0.07 | 90.25 |
| free cash flow yield | 0.01 | 0.04 | -67.05 |
| debt to equity | 2.58 | 2.62 | -1.40 |
| debt to assets | 0.5 | 0.5 | 0.03 |
| net debt to ebitda | 20.06 | -22.07 | 190.88 |
| current ratio | 1.41 | 1.33 | 5.83 |
| interest coverage | 0.43 | 0.57 | -24.89 |
| income quality | -1.9 | -0.63 | -201.12 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.03 | 0.03 | 3.91 |
| intangibles to total assets | 0.55 | 0.55 | 0.63 |
| capex to operating cash flow | 0.01 | 0.01 | 22.16 |
| capex to revenue | 0.0 | 0.0 | -9.55 |
| capex to depreciation | 0.01 | 0.01 | -11.36 |
| stock based compensation to revenue | 0.01 | 0.02 | -38.83 |
| graham number | 1.95 | 4.46 | -56.31 |
| roic | 0.01 | 0.01 | 0.53 |
| return on tangible assets | -0.01 | -0.07 | 79.14 |
| graham net net | -6.18 | -6.62 | 6.75 |
| working capital | 87196000 | 77420000 | 12.63 |
| tangible asset value | -235438000 | -242952000 | 3.09 |
| net current asset value | -283971000 | -294228000 | 3.49 |
| invested capital | 548671000 | 551738000 | -0.56 |
| average receivables | 129615000 | 131423000 | -1.38 |
| average payables | 20643000 | 21768000 | -5.17 |
| average inventory | 88819000 | 92305500 | -3.78 |
| days sales outstanding | 78.96 | 81.72 | -3.37 |
| days payables outstanding | 33.39 | 44.3 | -24.63 |
| days of inventory on hand | 178.43 | 158.83 | 12.34 |
| receivables turnover | 1.14 | 1.1 | 3.49 |
| payables turnover | 2.7 | 2.03 | 32.68 |
| inventory turnover | 0.5 | 0.57 | -10.98 |
| roe | -0.03 | -0.16 | 79.60 |
| capex per share | 0.0 | 0.0 | -18.41 |
ROE: Return on Equity (ROE) increased to -0.03 on 2024-09-28 Q3 from -0.16 on 2024-06-29 Q2, representing a change of 79.60%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -39.37 on 2024-09-28 Q3 from -3.84 on 2024-06-29 Q2, representing a change of -925.69%. Indicating a decrease in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 2.58 on 2024-09-28 Q3 from 2.62 on 2024-06-29 Q2, representing a change of -1.40%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. However, a ratio of 2.0 or higher is usually considered risky.
Current Ratio: Current Ratio increased to 1.41 on 2024-09-28 Q3 from 1.33 on 2024-06-29 Q2, representing a change of 5.83%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Negative Sentiment: Discounted Cash Flow value is 3.75 which is lower than current price 10.04, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-03 12:00:37
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
Sentiment: Positive
Publish Date: 2025-01-02 08:00:00
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company's core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity.
Sentiment: Neutral
Publish Date: 2024-12-23 10:40:32
Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Sentiment: Positive
Publish Date: 2024-12-06 10:55:30
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sentiment: Positive
Publish Date: 2024-11-05 12:26:31
Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Senior Vice President and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - J.P. Morgan Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call.
Sentiment: Positive
Publish Date: 2024-11-05 09:45:36
Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-05 07:30:00
DURHAM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 28, 2024.
Sentiment: Negative
Publish Date: 2024-11-04 10:45:48
Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Sentiment: Negative
Publish Date: 2024-10-29 10:35:31
Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.
Sentiment: Positive
Publish Date: 2024-10-29 07:30:00
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
Sentiment: Positive
Publish Date: 2024-10-22 10:35:23
BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
